Now we wait.
There is this
Analyst Actions: Barclays Adjusts BioCryst Pharmaceuticals PT to $13 From $9, Maintains Overweight Rating
BY MT Newswires
— 12:21 PM ET 02/26/2021
But you all know that we know better than the analysts. There is the R&D day March 22. I'm thinking good chance of bump to $15 on Q1 report (early June) and $20 by end of year.